Total Payments
$300,862
2024 Payments
$23,471
Companies
55
Transactions
1,424
Medicare Patients
15,234
Medicare Billing
$2.7M
Payment Breakdown by Category
Other$194,451 (64.6%)
Consulting$60,903 (20.2%)
Food & Beverage$31,351 (10.4%)
Travel$13,253 (4.4%)
Education$903.48 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $194,451 | 139 | 64.6% |
| Consulting Fee | $60,903 | 46 | 20.2% |
| Food and Beverage | $31,351 | 1,143 | 10.4% |
| Travel and Lodging | $13,253 | 70 | 4.4% |
| Education | $903.48 | 26 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mylan Specialty L.P. | $186,695 | 299 | $0 (2024) |
| Circassia Pharmaceuticals Inc | $46,447 | 70 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $25,597 | 67 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $16,908 | 111 | $0 (2024) |
| Grifols USA, LLC | $8,382 | 107 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $1,940 | 56 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,815 | 142 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,702 | 91 | $0 (2024) |
| United Therapeutics Corporation | $1,093 | 47 | $0 (2024) |
| GENZYME CORPORATION | $944.88 | 32 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,471 | 168 | AstraZeneca Pharmaceuticals LP ($11,475) |
| 2023 | $69,666 | 212 | Mylan Specialty L.P. ($59,687) |
| 2022 | $45,842 | 128 | Mylan Specialty L.P. ($43,694) |
| 2021 | $20,430 | 122 | Mylan Specialty L.P. ($18,455) |
| 2020 | $17,998 | 143 | Mylan Specialty L.P. ($16,259) |
| 2019 | $47,392 | 270 | Mylan Specialty L.P. ($44,168) |
| 2018 | $29,353 | 203 | Sunovion Pharmaceuticals Inc. ($16,080) |
| 2017 | $46,709 | 178 | Circassia Pharmaceuticals Inc ($35,598) |
All Payment Transactions
1,424 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: ANTIBIOTIC | ||||||
| 12/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $33.50 | General |
| Category: RESPIRATORY | ||||||
| 12/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $34.17 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | PFIZER INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA, CUTAQUIG | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/12/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $39.10 | General |
| Category: Cardiology | ||||||
| 12/12/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $2.63 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $0.44 | General |
| Category: RESPIRATORY | ||||||
| 12/10/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: Respiratory | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $33.78 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: Inflammation | ||||||
| 11/18/2024 | Baxter Healthcare | Hillrom - Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: Airway Clearance Device | ||||||
| 11/14/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $23.49 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $129.03 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | PFIZER INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA, CUTAQUIG | Food and Beverage | In-kind items and services | $24.58 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $21.84 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $26.56 | General |
| Category: RESPIRATORY | ||||||
| 11/11/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $24.98 | General |
| Category: HFCWO | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $10.37 | General |
| Category: RESPIRATORY | ||||||
| 11/04/2024 | Vifor Pharma, Inc. | Zemaira (Drug) | Food and Beverage | In-kind items and services | $28.13 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 3,881 | 28,409 | $3.1M | $829,237 |
| 2022 | 41 | 3,850 | 29,787 | $2.9M | $862,653 |
| 2021 | 40 | 4,283 | 16,262 | $1.7M | $642,452 |
| 2020 | 34 | 3,220 | 7,415 | $825,130 | $348,272 |
Total Patients
15,234
Total Services
81,873
Medicare Billing
$2.7M
Procedure Codes
146
All Medicare Procedures & Services
146 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2356 | Injection, tezepelumab-ekko, 1 mg | Office | 2023 | 18 | 20,580 | $1.2M | $267,689 | 21.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 899 | 1,906 | $551,430 | $172,908 | 31.4% |
| J1599 | Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg | Office | 2023 | 14 | 1,322 | $620,001 | $166,486 | 26.9% |
| 94626 | Professional services for outpatient pulmonary rehabilitation with continuous monitoring of blood oxygen, per session | Office | 2023 | 50 | 877 | $134,181 | $51,291 | 38.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 308 | 308 | $118,416 | $36,605 | 30.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 541 | 557 | $74,732 | $23,747 | 31.8% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 531 | 547 | $67,797 | $21,790 | 32.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 542 | 565 | $71,755 | $15,788 | 22.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 25 | 198 | $41,580 | $9,698 | 23.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 63 | 76 | $28,840 | $9,674 | 33.5% |
| 32555 | Aspiration of fluid from chest cavity using imaging guidance | Office | 2023 | 18 | 27 | $20,592 | $6,677 | 32.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 44 | 46 | $16,468 | $6,450 | 39.2% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 197 | 222 | $15,540 | $5,687 | 36.6% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 17 | 217 | $23,870 | $3,381 | 14.2% |
| 92507 | Treatment of speech, language, voice, communication, and/or hearing processing disorder | Office | 2023 | 28 | 64 | $8,128 | $3,154 | 38.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 53 | $9,191 | $2,869 | 31.2% |
| 92526 | Treatment of swallowing and feeding disorder | Office | 2023 | 19 | 44 | $6,072 | $2,780 | 45.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 12 | 16 | $15,700 | $2,610 | 16.6% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 141 | 170 | $7,276 | $2,297 | 31.6% |
| 76604 | Ultrasound scan of chest | Office | 2023 | 42 | 56 | $7,896 | $2,200 | 27.9% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 103 | 120 | $6,009 | $2,002 | 33.3% |
| 92524 | Analysis of voice and resonance production | Office | 2023 | 24 | 24 | $3,648 | $1,987 | 54.5% |
| 92612 | Evaluation and recording of swallowing using an endoscope | Office | 2023 | 14 | 14 | $3,920 | $1,981 | 50.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $3,936 | $1,977 | 50.2% |
| 31579 | Exam to assess movement of vocal cord flaps using an endoscope | Office | 2023 | 11 | 11 | $3,817 | $1,713 | 44.9% |
About Dr. Mark Pamer, D.O
Dr. Mark Pamer, D.O is a Critical Care Medicine healthcare provider based in Port Saint Lucie, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1184824542.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Pamer, D.O has received a total of $300,862 in payments from pharmaceutical and medical device companies, with $23,471 received in 2024. These payments were reported across 1,424 transactions from 55 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($194,451).
As a Medicare-enrolled provider, Pamer has provided services to 15,234 Medicare beneficiaries, totaling 81,873 services with total Medicare billing of $2.7M. Data is available for 4 years (2020–2023), covering 146 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease, Critical Care Medicine
- Location Port Saint Lucie, FL
- Active Since 07/23/2007
- Last Updated 10/17/2025
- Taxonomy Code 207RC0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1184824542
Products in Payments
- Yupelri (Drug) $159,811
- NIOX VERO DEVICE (Device) $46,052
- YUPELRI (Drug) $23,420
- UTIBRON (Drug) $22,154
- AIRSUPRA (Drug) $15,202
- Prolastin-C Liquid (Biological) $5,006
- LONHALA MAGNAIR (Drug) $3,346
- Xembify (Biological) $2,964
- DUPIXENT (Biological) $1,329
- UPTRAVI (Drug) $1,146
- SMARTVEST (Device) $930.24
- OFEV (Drug) $851.29
- TRELEGY ELLIPTA (Drug) $738.31
- TEZSPIRE (Biological) $716.49
- OPSUMIT (Drug) $677.13
- TYVASO (Drug) $604.09
- HYQVIA (Biological) $557.04
- GLASSIA (Biological) $550.27
- NUCALA (Biological) $532.26
- STIOLTO RESPIMAT (Drug) $476.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.